All News

On NET Cancer Day, a return visit for an over-the-counter antidiarrheal illustrates how pharmacists can identify a symptom pattern and help patients seek evaluation.

Survodutide met noninferiority for 5-point MACE, supporting its safety in adults with obesity and established CV disease or elevated risk.

A community oncology pharmacist explains how seeing patients across the course of their diagnosis builds trust and why accessibility remains the field’s biggest challenge despite advances in AI.

Kristen Hartzell, PharmD, explains that advance data collection, pre-filled consent forms, and peer and vendor support can help long-term care pharmacies run more efficient flu vaccine clinics for older adults.

Adding the IL-15 agonist to frontline BCG improved responses in carcinoma in situ without new safety signals; full data are expected at an upcoming congress.

Getting patients vaccinated matters more than which COVID-19 vaccine they receive, says Jodi Longueil, PharmD.

The new agreement lets Hims & Hers patients obtain FDA-approved tirzepatide and orforglipron at Lilly’s self-pay prices.

The approval is supported by findings from the phase 3 OCEANIC-STROKE trial.

Pharmacists can plan career sabbaticals before retirement with smart savings, employer leave options, and intentional steps that balance their finances with their goals.

Like enzymes and coenzymes, monitoring devices and pharmacists may achieve more together than either can alone.

Biykem Bozkurt, MD, PhD, explains why survodutide's glucagon component called for a dedicated noninferiority trial in adults with obesity.

At SITC 2026, 10 of 15 patients with advanced melanoma responded to investigational amsokigene autoleucel at the recommended phase 2 dose, with 5 still in response 12 months after infusion.

Brooke Hudspeth, PharmD, explains how pharmacists help patients link glucose trends to meals, activity, medications, and medication timing.

In an interview with Pharmacy Times, Matthew Peery, PharmD, BCOP, discusses how updated chronic lymphocytic leukemia guidelines inform treatment selection and how pharmacists help patients manage adverse effects, navigate complex dosing schedules, and access medications.

Optimal medical therapy scores, discharge prescribing, and readmissions data can help pharmacists demonstrate the value of heart failure services.

Your expertise, adaptability, and dedication to patient care are what make this publication worth producing.

The glucagon/GLP-1 dual agonist did not raise major adverse cardiovascular event risk in adults with obesity, but GI-related discontinuations were high.

Every responsibility described in this issue depends on a pharmacy workforce with enough time and support to carry it.

Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.

Cody Parsons, PharmD, APh, BCCCP, says protected pharmacist access lets patients with heart failure be seen more often than typical clinic visits allow.

The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.

Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.

If gene therapies are expected to deliver decades of benefit, long-term evidence collection must be coordinated, useful to patients, and financially sustainable.

As kratom questions increase, many pharmacists and other health care professionals may remain unfamiliar with it and with the potential risks.

Pharmacists can work alongside dermatologists, nurses, and other health care professionals to help answer skin care–related questions and help patients understand trial outcomes.

Matthew Porteus, MD, PhD, highlighted preclinical advances in automated stem cell gene editing that could improve manufacturing scalability while supporting the development of next-generation genetic medicines.

Payer requirements, prescriber habits, and operational realities ultimately determine which ICI patients receive.

Accelerated approval for patients who progressed on platinum and immunotherapy brings a new mechanism—and a familiar toxicity profile.